Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole

European Neuropsychopharmacology

Volumn 18, Issue 12, 2008, Pages 897-907

  Kwon, Jun Soo ^a   Kim, Euitae ^a   Kang, Do Hyung ^a   Choi, Jung Seok ^a   Yu, Kyung Sang ^a   Jang, In Jin ^a   Shin, Sang Goo ^a   APLUS study group, ^b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University College of Medicine and Hospital ^*

Author keywords

ANKK1; Antipsychotics; C957T; Pharmacogenetics; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXTRAPYRAMIDAL SYNDROME; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCORING SYSTEM; TAQ1A GENE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POLYMORPHISM, GENETIC; PROLACTIN; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUINOLONES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; YOUNG ADULT;

EID: 53649088749     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.07.010     Document Type: Article

References (36)

1. Alenius M., Hammarlund-Udenaes M., Wadelius M., Dahl M.L., Hartvig P., and Lindstrom L. Genetic polymorphisms as indicators of response to antipsychotics. Eur. Neuropsychopharmacol. 17 (2007) S434
2. Arranz M., Collier D., Sodhi M., Ball D., Roberts G., Price J., Sham P., and Kerwin R. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346 (1995) 281-282
3. Baker R.W., Goldberg J.F., Tohen M., Milton D.R., Stauffer V.L., and Schuh L.M. The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute mania. Bipolar Disord. 4 (2002) 43-49
4. Bartlett E.J., Brodie J.D., Simkowitz P., Schlosser R., Dewey S.L., Lindenmayer J.P., Rusinek H., Wolkin A., Cancro R., and Schiffer W. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am. J. Psychiatry 155 (1998) 337-343
5. DeQuardo J.R. Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?. J. Clin. Psychiatry 65 (2004) 132-133
6. Duan J., Wainwright M.S., Comeron J.M., Saitou N., Sanders A.R., Gelernter J., and Gejman P.V. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet. 12 (2003) 205-216
7. Guzey C., Scordo M.G., Spina E., Landsem V.M., and Spigset O. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur. J. Clin. Pharmacol. 63 (2007) 233-241
8. Hirvonen M., Laakso A., Nagren K., Rinne J.O., Pohjalainen T., and Hietala J. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol. Psychiatry 9 (2004) 1060-1061
9. Jonsson E.G., Nothen M.M., Grunhage F., Farde L., Nakashima Y., Propping P., and Sedvall G.C. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 4 (1999) 290-296
10. Kapur S., and Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 50 (2001) 873-883
11. Kapur S., Zipursky R., Jones C., Remington G., and Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157 (2000) 514-520
12. Kasper S., Lerman M.N., McQuade R.D., Saha A., Carson W.H., Ali M., Archibald D., Ingenito G., Marcus R., and Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. 6 (2003) 325-337
13. Kim E., Kwon J.S., Shin Y.W., Lee J.S., Kang W.J., Jo H.J., Lee J.M., Yu K.S., Kang D.H., Cho J.Y., Jang I.J., and Shin S.G. Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers. Pharmacogenet. Genomics 18 (2008) 91-97
14. Kwon, J.S., Jang, J.H., Kang, D.H., Yoo, S.Y., Kim, Y.K., Cho, S.J., group t.A.s., submitted for publication. Long-term efficacy and safety of aripiprazole in Korean patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: a 26-week prospective study.
15. McDonald J., Barnes T.A., Okawa H., Williams J., Calo G., Rowbotham D.J., and Lambert D.G. Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system. Br. J. Pharmacol. 140 (2003) 61-70
16. Mihara K., Kondo T., Suzuki A., Yasui N., Nagashima U., Ono S., Otani K., and Kaneko S. Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene. Psychopharmacology (Berl) 149 (2000) 246-250
17. Mihara K., Suzuki A., Kondo T., Yasui-Furukori N., Ono S., Otani K., Kaneko S., and Inoue Y. Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am. J. Med. Genet. 105 (2001) 271-274
18. Moeller F.G., Chen Y.W., Steinberg J.L., Petty F., Ripper G.W., Shah N., and Garver D.L. Risk factors for clozapine discontinuation among 805 patients in the VA hospital system. Ann. Clin. Psychiatry 7 (1995) 167-173
19. Neville M.J., Johnstone E.C., and Walton R.T. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Human Mutat. 23 (2004) 540-545
20. Ngan E.T., Lane C.J., Ruth T.J., and Liddle P.F. Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naive schizophrenic patients: correlations with symptom change. J. Neurol. Neurosurg. Psychiatry 72 (2002) 106-110
21. Noble E.P., Blum K., Ritchie T., Montgomery A., and Sheridan P.J. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch. Gen. Psychiatry 48 (1991) 648-654
22. Pohjalainen T., Rinne J.O., Nagren K., Lehikoinen P., Anttila K., Syvalahti E.K., and Hietala J. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry 3 (1998) 256-260
23. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., and Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60 (2003) 681-690
24. Raja M. Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole. Int. J. Neuropsychopharmacol. (2006) 1-4
25. Ramaswamy S., Vijay D., William M., Sattar S.P., Praveen F., and Petty F. Aripiprazole possibly worsens psychosis. Int. Clin. Psychopharmacol. 19 (2004) 45-48
26. Reeves R.R., and Mack J.E. Worsening schizoaffective disorder with aripiprazole. Am. J. Psychiatry 161 (2004) 1308
27. Rosenheck R., Lawson W., Crayton J., Cramer J., Xu W., Thomas J., Stolar M., and Charney D. Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Biol. Psychiatry 44 (1998) 475-482
28. Salin-Pascual R.J., Herrera-Estrella M., Galicia-Polo L., Rosas M., and Brunner E. Low delta sleep predicted a good clinical response to olanzapine administration in schizophrenic patients. Rev. Invest. Clin. 56 (2004) 345-350
29. Schafer M., Rujescu D., Giegling I., Guntermann A., Erfurth A., Bondy B., and Moller H.J. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am. J. Psychiatry 158 (2001) 802-804
30. Silvestri S., Seeman M.V., Negrete J.C., Houle S., Shammi C.M., Remington G.J., Kapur S., Zipursky R.B., Wilson A.A., Christensen B.K., and Seeman P. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 152 (2000) 174-180
31. Suzuki A., Mihara K., Kondo T., Tanaka O., Nagashima U., Otani K., and Kaneko S. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 10 (2000) 335-341
32. Suzuki A., Kondo T., Otani K., Mihara K., Yasui-Furukori N., Sano A., Koshiro K., and Kaneko S. Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. Am. J. Psychiatry 158 (2001) 1714-1716
33. Thompson J., Thomas N., Singleton A., Piggott M., Lloyd S., Perry E.K., Morris C.M., Perry R.H., Ferrier I.N., and Court J.A. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7 (1997) 479-484
34. Yoshimura R., Ueda N., Shinkai K., and Nakamura J. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. Int. Clin. Psychopharmacol. 18 (2003) 107-111
35. Young R.M., Lawford B.R., Barnes M., Burton S.C., Ritchie T., Ward W.K., and Noble E.P. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br. J. Psychiatry 185 (2004) 147-151
36. Zai C.C., Hwang R.W., De Luca V., Muller D.J., King N., Zai G.C., Remington G., Meltzer H.Y., Lieberman J.A., Potkin S.G., and Kennedy J.L. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int. J. Neuropsychopharmacol. (2006) 1-13